Search | IOVS | ARVO Journals

Showing 1 – 18 of 18

SORT: Best Match Most Recent Oldest

VIEW: Basic | Expanded

Retina April 2025

Structural Updates to the Implant and Refill Needle of the Port Delivery Platform

PDF

Dante J. Pieramici; Peter A. Campochiaro; Margaret Chang; Ian Pearce; Carl D. Regillo; Shamika Gune; Nancy Holekamp; Carlos Quezada-Ruiz; Shrirang V. Ranade; Natasha Singh; Geoffrey Wise; Joshua Horvath
TAGS: implants, needles
Trans. Vis. Sci. Tech.. 2025; 14(4):8. https://doi.org/10.1167/tvst.14.4.8

Includes: Multimedia, Supplemental Content

ARVO Annual Meeting Abstract June 2024

Port Delivery System With Ranibizumab (PDS) in diabetic macular edema (DME): additional primary analysis results of the phase 3 Pagoda trial

Varun Malhotra; Michael A. Klufas; Dennis M Marcus; Jordan M Graff; Peter A Campochiaro; Salman Rahman; Paul Latkany; Shamika Gune; Stephanie DeGraaf; Ashwini Bobbala; Mel Rabena; Carlos Ruiz; Arshad M. Khanani

Invest. Ophthalmol. Vis. Sci.. 2024; 65(7):6233.

ARVO Annual Meeting Abstract June 2023

Long-term efficacy and safety of the Port Delivery System with ranibizumab in patients with neovascular age-related macular degeneration: Results from the Portal 5-year subgroup analysis

James Howard; Melina Cavichini Cordeiro; Natasha Singh; Shamika Gune

Invest. Ophthalmol. Vis. Sci.. 2023; 64(8):2188.

ARVO Annual Meeting Abstract June 2022

Aqueous humor vascular endothelial growth factor pharmacodynamics in the phase 3 Archway trial of the Port Delivery System with ranibizumab

Murtaza Adam; Laura Barras; Mauricio Maia; Shamika Gune; Katie Maass; Michael Chang

Invest. Ophthalmol. Vis. Sci.. 2022; 63(7):4285.

ARVO Annual Meeting Abstract June 2022

Archway phase 3 trial of the Port Delivery System with ranibizumab (PDS) for neovascular AMD: end-of-study results

ROBERT MITTRA; Logan Brooks; Charles Wykoff; Natalia Callaway; Stephanie DeGraaf; Anne Fung; Shamika Gune; Sophie LePogam; Robert Smith; Jeffrey Willis; Giulio Barteselli

Invest. Ophthalmol. Vis. Sci.. 2022; 63(7):3121.

ARVO Annual Meeting Abstract June 2021

Pharmacokinetic profile of the Port Delivery System with ranibizumab (PDS) in the phase 3 Archway trial

Peter A Campochiaro; Shamika Gune; Mauricio Maia; Han Ting Ding; Katie Maass

Invest. Ophthalmol. Vis. Sci.. 2021; 62(8):350.

ARVO Annual Meeting Abstract June 2020

Ladder Phase 2 Trial of the Port Delivery System With Ranibizumab (PDS) for Neovascular AMD: End of Study Results

Franco Recchia; Steven Blotner; Natasha Singh; Giulio Barteselli; Shamika Gune

Invest. Ophthalmol. Vis. Sci.. 2020; 61(7):1155.

ARVO Annual Meeting Abstract June 2020

Pharmacokinetic (PK) Profile of the Port Delivery System with Ranibizumab (PDS) in the Phase 2 Ladder Trial

Peter A Campochiaro; Shamika Gune; Mauricio Maia; Katie Maass

Invest. Ophthalmol. Vis. Sci.. 2020; 61(7):1157.

ARVO Annual Meeting Abstract June 2020

Optimization of the Port Delivery System With Ranibizumab (PDS) Implant Insertion Procedure in the Ladder Phase 2 Trial

William R Freeman; Shamika Gune; Giulio Barteselli

Invest. Ophthalmol. Vis. Sci.. 2020; 61(7):3703.

ARVO Annual Meeting Abstract June 2020

Fluctuations in Central Foveal Thickness and Vision Outcomes With Anti-VEGF Therapy for Neovascular Age-Related Macular Degeneration

Veeral Sheth; Steven Blotner; Mila Malhotra; Mitchell D'Rozario; Shamika Gune

Invest. Ophthalmol. Vis. Sci.. 2020; 61(7):4224.

ARVO Annual Meeting Abstract July 2019

Relationship between sub retinal fluid (SRF) and vision outcomes in eyes with neovascular age-related macular degeneration (nAMD) in the HARBOR trial

Srinivas R Sadda; Avanti Ghanekar; Lauren Hill; Shamika Gune

Invest. Ophthalmol. Vis. Sci.. 2019; 60(9):5189.

ARVO Annual Meeting Abstract July 2018

Long-term outcomes in ranibizumab-treated East Asian patients with myopic choroidal neovascularization in the 36-month post-RADIANCE study period

Mark Wieland; Bann-mo Day; Tatiana Eccoffier; Shamika Gune; Zdenka Haskova

Invest. Ophthalmol. Vis. Sci.. 2018; 59(9):784.

ARVO Annual Meeting Abstract July 2018

A longitudinal SD-OCT analysis of macular atrophy in the HARBOR trial

Srinivas R. Sadda; Elizabeth Morgenthien; Shamika Gune

Invest. Ophthalmol. Vis. Sci.. 2018; 59(9):4481.

ARVO Annual Meeting Abstract June 2017

Posterior vitreous status did not impact ranibizumab treatment outcomes in HARBOR study patients with neovascular AMD

Michelle V Carle; Lauren Hill; Tatiana Ecoiffier; Shamika Gune

Invest. Ophthalmol. Vis. Sci.. 2017; 58(8):407.

ARVO Annual Meeting Abstract September 2016

Efficacy of ranibizumab therapy in eyes with neovascular AMD and pigment epithelial detachment (PED): a HARBOR subanalysis study

David Sarraf; Lauren Hill; Na Lu; Shamika Gune; Lisa Tuomi

Invest. Ophthalmol. Vis. Sci.. 2016; 57(12)

ARVO Annual Meeting Abstract September 2016

Ranibizumab induces regression of diabetic retinopathy (DR) in more than three-quarters of patients with high-risk non-proliferative diabetic retinopathy (NPDR) independent of retinal nonperfusion

Charles Clifton Wykoff; Shamika Gune; Lauren Hill; Miranda Hemphill; Zdenka Haskova

Invest. Ophthalmol. Vis. Sci.. 2016; 57(12)

ARVO Annual Meeting Abstract September 2016

Association between prior response to ranibizumab treatment and disease quiescence: Implications for AMD dosing

Rahul N. Khurana; Louis K Chang; Howard Shapiro; Avanti Ghanekar; Shamika Gune

Invest. Ophthalmol. Vis. Sci.. 2016; 57(12):3351.

ARVO Annual Meeting Abstract September 2016

Prevalence of drusen and conversion to neovascular age-related macular degeneration in the HARBOR study fellow eyes

Caroline R Baumal; Carlos Quezada Ruiz; Shamika Gune; Pin-wen Wang; Anne E Fung

Invest. Ophthalmol. Vis. Sci.. 2016; 57(12):4967.

NARROW

Content Type

Journal

Article Type

Topics

Tags

Filters

Specify Date Range

Structural Updates to the Implant and Refill Needle of the Port Delivery Platform

Port Delivery System With Ranibizumab (PDS) in diabetic macular edema (DME): additional primary analysis results of the phase 3 Pagoda trial

Long-term efficacy and safety of the Port Delivery System with ranibizumab in patients with neovascular age-related macular degeneration: Results from the Portal 5-year subgroup analysis

Aqueous humor vascular endothelial growth factor pharmacodynamics in the phase 3 Archway trial of the Port Delivery System with ranibizumab

Archway phase 3 trial of the Port Delivery System with ranibizumab (PDS) for neovascular AMD: end-of-study results

Pharmacokinetic profile of the Port Delivery System with ranibizumab (PDS) in the phase 3 Archway trial

Ladder Phase 2 Trial of the Port Delivery System With Ranibizumab (PDS) for Neovascular AMD: End of Study Results

Pharmacokinetic (PK) Profile of the Port Delivery System with Ranibizumab (PDS) in the Phase 2 Ladder Trial

Optimization of the Port Delivery System With Ranibizumab (PDS) Implant Insertion Procedure in the Ladder Phase 2 Trial

Fluctuations in Central Foveal Thickness and Vision Outcomes With Anti-VEGF Therapy for Neovascular Age-Related Macular Degeneration

Relationship between sub retinal fluid (SRF) and vision outcomes in eyes with neovascular age-related macular degeneration (nAMD) in the HARBOR trial

Long-term outcomes in ranibizumab-treated East Asian patients with myopic choroidal neovascularization in the 36-month post-RADIANCE study period

A longitudinal SD-OCT analysis of macular atrophy in the HARBOR trial

Posterior vitreous status did not impact ranibizumab treatment outcomes in HARBOR study patients with neovascular AMD

Efficacy of ranibizumab therapy in eyes with neovascular AMD and pigment epithelial detachment (PED): a HARBOR subanalysis study

Ranibizumab induces regression of diabetic retinopathy (DR) in more than three-quarters of patients with high-risk non-proliferative diabetic retinopathy (NPDR) independent of retinal nonperfusion

Association between prior response to ranibizumab treatment and disease quiescence: Implications for AMD dosing

Prevalence of drusen and conversion to neovascular age-related macular degeneration in the HARBOR study fellow eyes

To View More...

You must be signed into an individual account to use this feature.